Metabolic Dysfunction-Associated Steatohepatitis-Related Cirrhosis

The FDA has granted breakthrough therapy designation to Boehringer Ingelheim’s survodutide for the treatment of adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate or advanced fibrosis.

Survodutide was superior to placebo and significantly improved markers of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, according to data presented at EASL Congress.

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.